Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Operating Expenses        
Research and development expenses $ 427,109 $ 726,904 $ 925,855 $ 1,211,655
General and administrative expenses 374,878 410,072 859,255 807,837
Total operating expenses 801,987 1,136,976 1,788,110 2,019,492
Operating Loss (801,987) (1,136,976) (1,788,110) (2,019,492)
Other Income (Expense)        
Interest expense (19,280) (6,102) (36,450) (10,702)
Interest income 18 3,398 846 9,383
Total other income (expense) (19,262) (2,704) (35,604) (1,319)
Net Operating Loss Before Income Tax Benefit (821,249) (1,139,680) (1,823,714) (2,020,811)
Income Tax Benefit 87,835 170,602 215,964 300,901
Net Loss $ (733,414) $ (969,078) $ (1,607,750) $ (1,719,910)
Net Loss per Common Share - Basic and Diluted $ (0.13) $ (0.18) $ (0.29) $ (0.31)
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted 5,515,447 5,525,009 5,515,447 5,525,009